SAN

+0.43%↑

MRK1

120.65

+1.99%↑

SHL.DE

44.4

-0.45%↓

ARGX

724.6

+0.06%↑

FRE

47.26

-2.38%↓

SAN

+0.43%↑

MRK1

120.65

+1.99%↑

SHL.DE

44.4

-0.45%↓

ARGX

724.6

+0.06%↑

FRE

47.26

-2.38%↓

SAN

+0.43%↑

MRK1

120.65

+1.99%↑

SHL.DE

44.4

-0.45%↓

ARGX

724.6

+0.06%↑

FRE

47.26

-2.38%↓

SAN

+0.43%↑

MRK1

120.65

+1.99%↑

SHL.DE

44.4

-0.45%↓

ARGX

724.6

+0.06%↑

FRE

47.26

-2.38%↓

SAN

+0.43%↑

MRK1

120.65

+1.99%↑

SHL.DE

44.4

-0.45%↓

ARGX

724.6

+0.06%↑

FRE

47.26

-2.38%↓

Kodu・Aktsiate loetelu・Nanobiotix

N
Nanobiotix

Suletud

18.92 -0.84

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

18.32

Max

19.28

Põhinäitajad
By Trading Economics
Sissetulek	41M -5.4M
Müük	48M 27M
Kasumimarginaal	-20.208
Töötajad	103
EBITDA	46M 1.1M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+18.92% upside

Turustatistika
By TradingEconomics
Turukapital	-25M 882M
Eelmine avamishind	19.76
Eelmine sulgemishind	18.92

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bullish Evidence

2.975 / 3.015 Toetus ja vastupanu

Nanobiotix Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

15. dets 2025, 17:39 UTC

Suurimad hinnamuutused turgudel

Vanda Pharmaceuticals Rises on FDA Biologics License Application

15. dets 2025, 23:44 UTC

Market Talk

Gold Steady Ahead of U.S. Employment Report -- Market Talk

15. dets 2025, 23:38 UTC

Market Talk

Global Equities Roundup: Market Talk

15. dets 2025, 23:38 UTC

Market Talk

Nikkei May Fall, Tracking Wall Street's Decline -- Market Talk

15. dets 2025, 22:19 UTC

Market Talk

Clean-Energy Project Developers Benefit From 'Deep Buyer Universe' -- Market Talk

15. dets 2025, 21:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Tech, Media & Telecom Roundup: Market Talk

15. dets 2025, 21:42 UTC

Omandamised, ülevõtmised, äriostud

Comcast Spinoff Versant Debuts at Modest Valuation, a Signal for a Warner Bros. Sale -- Barrons.com

15. dets 2025, 21:32 UTC

Omandamised, ülevõtmised, äriostud

Comcast Spinoff Versant Debuts at Modest Valuation, Puts Warner Bros. Discovery in Focus -- Barrons.com

15. dets 2025, 21:28 UTC

Omandamised, ülevõtmised, äriostud

iRobot Files for Bankruptcy After Amazon Was Forced to Scrap Its Deal to Buy the Roomba Maker -- Barrons.com

15. dets 2025, 21:26 UTC

Omandamised, ülevõtmised, äriostud

Commercial Metals Completes Acquisition of Foley Products for $1.84B >CMC

15. dets 2025, 21:23 UTC

Omandamised, ülevõtmised, äriostud

Perseus Mining: Reserves Right to Make Further Proposal If Circumstances Change

15. dets 2025, 21:23 UTC

Omandamised, ülevõtmised, äriostud

Perseus Mining: Does Not Intend to Submit Revised Takeover Proposal For Predictive

15. dets 2025, 21:23 UTC

Omandamised, ülevõtmised, äriostud

Perseus Mining: Notes Predictive Shares Trade at Discount to Value Implied By Perseus Proposal

15. dets 2025, 21:22 UTC

Omandamised, ülevõtmised, äriostud

Perseus Mining: Believes Revised Robex Merger Inferior to Its Own Takeover Proposal

15. dets 2025, 21:20 UTC

Omandamised, ülevõtmised, äriostud

Commercial Metals Completes Acquisition Of Foley Products Company >CMC

15. dets 2025, 21:15 UTC

Omandamised, ülevõtmised, äriostud

ServiceNow Completes Acquisition Of Moveworks >NOW

15. dets 2025, 21:00 UTC

Omandamised, ülevõtmised, äriostud

Comcast Spinoff Versant Debuts at Low Valuation; Could Figure in Warner Bros. Discovery Takeover Battle -- Barrons.com

15. dets 2025, 20:57 UTC

Omandamised, ülevõtmised, äriostud

Comcast Spinoff Versant Debuts at Low Valuation; Could Figure in Warner Bros. Discovery Takeover Battle -- Barrons.com

15. dets 2025, 20:36 UTC

Market Talk

Oil Futures Fall Further on Oversupply Concerns -- Market Talk

15. dets 2025, 20:31 UTC

Market Talk

U.S. Natural Gas Futures Extend Losing Streak -- Market Talk

15. dets 2025, 20:27 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

ServiceNow's Acquisition Streak Could Cause Investor Angst -- Market Talk

15. dets 2025, 20:15 UTC

Market Talk

El Buen Fin Helps Lift Mexican November Retail Sales -- Market Talk

15. dets 2025, 19:22 UTC

Market Talk

Gold and Silver Gain to Start Week -- Market Talk

15. dets 2025, 18:37 UTC

Market Talk

Oil Futures Extend Losses On Oversupply Worries -- Market Talk

15. dets 2025, 18:29 UTC

Market Talk

ServiceNow Seen Facing Pressure if Government Budgets Decline -- Market Talk

15. dets 2025, 17:58 UTC

Market Talk

Canada Housing Market In Search Of a Bottom -- Market Talk

15. dets 2025, 17:36 UTC

Market Talk

Canada Data Signal Underlying Price Pressures Persist -- Market Talk

15. dets 2025, 17:36 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15. dets 2025, 17:36 UTC

Tulu

Texas Instruments Stock Slips. It Caught a Rare Downgrade From Goldman Sachs. -- Barrons.com

15. dets 2025, 17:30 UTC

Omandamised, ülevõtmised, äriostud

Cinemark Stock Could Fall Even More If Netflix Buys Warner Bros., Analyst Says -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Nanobiotix Prognoos

Hinnasiht

By TipRanks

18.92% tõus

12 kuu keskmine prognoos

Keskmine 23 EUR 18.92%

Kõrge 25 EUR

Madal 21 EUR

Põhineb 3 Wall Streeti analüütiku instrumendi Nanobiotix 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

3 ratings

Osta

Hoia

Müü

Põhineb 3 analüütiku instrumendi Nanobiotix aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

2.975 / 3.015Toetus ja vastupanu

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Nanobiotix

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.